This morning the Full Court published its decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161 confirming that pharmaceutical formulation patents are no longer eligible for a patent term extension in Australia.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 28 November 2025 are set out below…
We are delighted to welcome Amanda Griffiths to Pearce IP as Executive Lawyer & Trade Mark Attorney and Head of Trade Marks (NZ). Amanda is one of New Zealand’s most experienced and respected brand protection professionals, with nearly 25 years’ experience…
Founder and CEO of Pearce IP, Naomi Pearce, has been recognised as the 2026 Client Choice Award winner for Intellectual Property – Patents (Australia) by Lexology. Established in 2005, the Client Choice Awards celebrate those law firms and partners around the world who stand apart for the excellence of their client care and quality of service.
The Australian Federal Court addressed when a successful applicant in patent infringement proceedings must make an election between damages and an account of profits. The answer is: promptly, once they are in a sufficiently informed position to make a meaningful decision.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 21 November 2025 are set out below…
Two years ago, Pearce IP made the decision to put its employee’s first by introducing a raft of reproductive leave options for all permanent employees. With a workforce that’s 88% female and witnessing the impact of…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 14 November 2025 are set out below…
Pearce IP’s CEO & Founder Naomi Pearce recognised in IAM Global Leaders 2026 which showcases patent leaders in IAM Patent 1000 gold tier who merit special attention.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 7 November 2025 are set out below…
In a lengthy judgment, Justice Nicholas of the Federal Court of Australia has dismissed Sanofi’s appeal to overturn the decision of the Delegate of the Commissioner of Patents dismissing Sanofi’s opposition to the grant of five Amgen patent applications…
We have previously reported, twice, on the New Zealand government’s policy to allow the advertisement at medical conferences and trade shows of medicines not approved by the New Zealand medicines regulator, Medsafe.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 October 2025 are set out below…
When is a trade mark application filed in bad faith? Pearce IP’s Kimberley Evans discusses the recent trade mark decision of Rallen Australia Pty Limited v Tamboran Resources...
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 October 2025 are set out below…
This case was a successful application by Miele, the world-renowned cooking appliance manufacturer, to revoke relevant claims of AU2012247900 entitled “Hob with central removal of cooking vapours by suction-extraction in the downward direction” (the Patent), owned by the respondent, Bruckbauer.
Naomi Pearce, Pearce IP’s founder and CEO has been recognised as one of 70 Elite Women for 2025 by Australasian Lawyer, standing as a powerful symbol of what leadership can foster when excellence is balanced with the ability to allow others to thrive.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 October 2025 are set out below…
UPDATE: New Zealand intends to allow advertising of unapproved drugs at medical professional conferences…later. Earlier this year we reported on the New Zealand government’s announcement of a policy…
Pearce IP’s CEO, Naomi Pearce, discusses trends in preliminary injunctions in Australian life sciences patent cases with Head of Litigation (Australia), Helen Macpherson, following the recent Federal Court refusal of Regeneron’s and Bayer’s patent PI application against Sandoz relating to their AUD$500M/year blockbuster aflibercept (Eylea®).
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 10 October 2025 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 3 October 20252025 are set out below…
The Federal Court of Australia has handed down judgment in proceedings between Perfect Day, Inc. and the Commissioner of Patents, in an appeal from an opposition decision concerning a patent application for dairy substitute food compositions. Justice Rofe dismissed Perfect Day’s appeal and refused to allow…
Justice Moshinsky of the Federal Court has delivered judgment in patent proceedings between The NOCO Company (NOCO) and Brown & Watson International Pty Ltd (B&W) relating to portable vehicle battery jump starters.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
